Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2–Expressing Metastatic Breast Cancer

Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate with a topoisomerase I payload that targets the human epidermal growth factor receptor 2 (HER2). T-DXd is approved for patients with previously treated HER2-positive or HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/ISH−) metastatic/unr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Crossno, Christine L., Gesthalter, Yaron B., Kelley, Kristen, Moore, Heather B., Rimawi, Mothaffar F., Westbrook, Kelly E., Buys, Saundra S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424906/
https://www.ncbi.nlm.nih.gov/pubmed/37207306
http://dx.doi.org/10.1200/OP.22.00480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424906/
https://www.ncbi.nlm.nih.gov/pubmed/37207306
http://dx.doi.org/10.1200/OP.22.00480

Ejemplares similares